Identifying antibodies that target systemic amyloid deposition

识别针对系统性淀粉样蛋白沉积的抗体

• 批准号: 2105621
• 金额: --
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2105621
• 关键词: Identifying; antibodies; target; systemic; amyloid

Amyloid deposition is a worldwide burden associated with a range of largely age-associated diseases. However, the mechanisms underlying the process of amyloid aggregation and possible strategies for degradation are still not fully understood. The aim of this project is to use 6 amyloid-forming proteins (light chain proteins - lambda and kappa, apolipoprotein, transthyretin, lysozyme and fibrinogen) to design antibodies that can bind to different protein forms associated with the aggregation process (monomer, oligomer, fibril). The structural implications of this binding will be fully characterised using a range of structural biology and complementary techniques. This will enhance understanding of the aggregation process and provide opportunity for further development of the antibodies to target the proteins for degradation as a future therapeutic option and to improve quality of life for the ageing population. The high throughput antibody screening facilities available at UCB enable this project to exploit new ways of working to discover and validate new therapeutic agents and bioactive molecules with increased efficiency and reduced cost. It also bridges academia and industry collaborations promoting innovation and partnerships.

淀粉样蛋白沉积是一种全球性负担，与一系列主要与年龄相关的疾病相关。然而，淀粉样蛋白聚集过程的机制和可能的降解策略仍然没有完全理解。该项目的目的是使用6种淀粉样蛋白形成蛋白（轻链蛋白-λ和κ、载脂蛋白、甲状腺素运载蛋白、溶菌酶和纤维蛋白原）来设计可以结合与聚集过程相关的不同蛋白形式（单体、寡聚体、原纤维）的抗体。这种结合的结构影响将使用一系列结构生物学和互补技术进行充分表征。这将增强对聚集过程的理解，并为进一步开发抗体提供机会，以靶向蛋白质进行降解，作为未来的治疗选择，并改善老年人群的生活质量。UCB提供的高通量抗体筛选设施使该项目能够利用新的工作方式来发现和验证新的治疗药物和生物活性分子，提高效率并降低成本。它还为促进创新和伙伴关系的学术界和工业界合作搭建了桥梁。